Rising at a CAGR of 5.6% from 2022 to 2029, arthropod-borne viral infections testing demand is estimated to attain a valuation of USD 1.3 Billion by end of the forecast period. The global Arthropod-Borne Viral Infections Testing Market is worth USD 1.9 Billion in 2022.
| Attribute | Details |
|---|---|
| Arthropod-borne Viral Infections Testing Market Size (2022) | USD 1.3 Billion |
| Predicted Net Worth (2029) | USD 1.9 Billion |
| Global Market Growth Metrics (2022 to 2029) | 5.6% CAGR |
| Market Share of ELISA-based Tests | 52% |
Arboviral diseases are infections caused by virus spread among humans through the bites of arthropods. Common arthropods through which diseases are spread are mosquitoes and ticks. Arthropod-borne viral infections testing accounts for 4.4% of the global infectious disease diagnostics market, which stood at USD 28 Billion in 2021.
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
| Particulars | Details |
|---|---|
| H1, 2021 | 5.64% |
| H1, 2022 Projected | 5.63% |
| H1, 2022 Outlook | 3.83% |
| BPS Change - H1, 2022 (O) - H1, 2022 (P) | (-) 180 ↓ |
| BPS Change - H1, 2022 (O) - H1, 2021 | (-) 181 ↓ |
The variation between the BPS values observed within the arthropod-borne viral infections testing market in H1, 2022 - outlook over H1, 2022 projected reflects a decline by 180 BPS units. Additionally, a value BPS decline in H1-2022 over H1-2021 by 181 Basis Point Share (BPS) is demonstrated by the market.
The market observes a decline in the BPS values owed to the poor accessibility of detection methods in low-income economies with a large disease burden. As a result, high costs of healthcare facilities along with a lack of awareness about infectious diseases are expected to restrain the market's growth.
The market is subjected to several macro economical and industry variables, which include disease epidemiology, biologics licensing, product patenting and distribution licensing.
Factors such as climate change, urbanization, and global trade can expand the geographic distribution of vectors and associated arboviruses, thus increasing the potential disease burden in susceptible hosts. This factor can present an opportunity for a positive growth outlook for the market
Healthcare has become an area of prime concern across the world and this is due to the rising diseases and infections across the world. There has been a substantial rise in arboviral diseases over the past few years and this has influenced demand for arthropod-borne viral infections testing.
Arthropod-borne viral infections testing demand rose at a CAGR of 4.9% from 2014 to 2021 and ended up with a market worth of USD 1.2 Billion in 2021.
Most common arthropod-borne viral infection in the world according to WHO (World Health Organization) is dengue, with the potential risk to infect more than 30% of the world’s population.
Rising focus on public healthcare, increasing travel and trade activities on a global scale, changing lifestyle trends, environmental and climatic changes, rapid urbanization across the world, etc. are some major factors that influence arthropod-borne viral infections testing market potential on a global scale.
The market for arthropod-borne viral infections testing is anticipated to rise at a CAGR of 5.6% over the forecast period of 2022 to 2029.
Re-emergence of Arthropod-borne Viral Infections to Drive Demand
Arthropod-borne infections have proven to be responsible for widespread epidemics across the world. Some of the notable arboviral epidemics are of dengue and Zika virus which led to further complications in the population infected.
These epidemics have been dealt with to a certain extent but have proven their re-emergence in recent times which is a major factor that drives demand for arthropod-borne viral infections testing on a global level. The unpredictable nature of these infections promotes arthropod-borne viral infections testing providers to develop better diagnostic solutions to detect and avoid a community spread of these infections.
Increasing Government Initiatives to Limit Risk of Arboviral Infections
Governments across the world are working in sync with health organizations to mitigate the risk of arthropod-borne viral infections. As a matter of public safety, the focus on these diseases is increasing in the past few years with severe outbreaks being recorded across the world. The emergence of coronavirus in 2020 has further bolstered the importance of government inclusion in matters of public health.
For instance, a pilot program funded by Global Emerging Infectious Surveillance (GEIS) a division of Armed Forces Health Surveillance Branch of the USA is set to launch in spring of 2022 to identify emerging infectious diseases and mitigate risk. This is expected to be attained by a global laboratory network that is designed to enhance global health security.
MEA and Latin America to Provide Major Opportunities for Market Players
This FMI industry analysis provides metrics for the arthropod-borne viral infections testing market across regions such as North America, Latin America, Europe, East Asia, South Asia & Pacific, and the Middle East & Africa (MEA).
The market for arthropod-borne viral infections testing in Latin America is anticipated to see high demand over the forecast period as it accounts for a notable number of infections across the world.
Developing healthcare infrastructure and rising awareness about arthropod-borne infections is anticipated to influence arthropod-borne viral infections testing demand in this region.
Demand for arthropod-borne viral infections testing in North America is expected to be low as the incidence of arboviral infections and diseases in this region is low. Advanced healthcare infrastructure and proper preventive care reduce the chances of infection in this region.
East Asia and South Asia are expected to see high demand for arthropod-borne viral infections testing over the forecast period. Implementation of stringent regulations to curb the spread of infectious diseases in this region is anticipated to drive market potential in these regions.
Densely populated countries like India and China are expected to emerge as highly lucrative markets for arthropod-borne viral infections testing vendors.
Rising instances of arboviral infections and epidemics in the MEA region are expected to majorly drive demand for arthropod-borne viral infections testing in this region. This region is expected to be one of the most important markets on a global level owing to the re-emergence of multiple infections like Zika virus and others.
Underdeveloped healthcare infrastructure is a major restraining factor for arthropod-borne viral infections testing market in the MEA region.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
Increasing Threat of Arboviral Infections Augmenting Market Expansion
Instances of arthropod-borne viral infections have been increasing in the UK in recent times and this is anticipated to drive arthropod-borne viral infections testing demand in the nation. Lyme disease has become a prominent issue in the UK over recent years and other arthropod-borne diseases have also seen an increase in incidence.
Increasing global travel and trade are expected to fuel the adoption of arthropod-borne viral infections testing in the UK
Developing Healthcare Infrastructure to Provide Lucrative Market Opportunities
Brazil is anticipated to be a highly rewarding market for arthropod-borne viral infections testing vendors due to high incidence of multiple arthropod-borne viral infections like Zika virus and dengue. Brazil is a developing economy and has an emerging healthcare infrastructure that has a lot of untapped potential that arthropod-borne viral infections testing providers can unlock if they enter this market.
High Preference for ELISA-based Test Kits to Drive Sales through 2029
Enzyme-linked immunosorbent assay (ELISA)-based tests have been immensely popular in the arthropod-borne viral infections testing marketplace over the past few years and currently account for a dominant market share of 52% in the global landscape.
Increasing preference for use of ELISA-based test kits by patients, healthcare professionals, researchers, etc. is expected to propel its popularity further.
In 2022, reverse-transcription polymerase chain reaction (RT-PCR) kits hold a market share of 33.5% in the global arthropod-borne viral infections testing industry. The COVID-19 pandemic boosted demand for RT-PCR test kits and this trend is expected to be prevalent over the forecast period as well.
Arthropod-borne viral infections testing providers are investing in the research and development of rapid test kits that are effective in diagnosing infections in a short period of time with minimal error.
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2029 |
| Historical Data Available for | 2014 to 2021 |
| Market Analysis | USD Million for Value |
| Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia & Pacific; Middle East & Africa (MEA) |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Germany, UK, France, Spain, Italy, China, Japan, South Korea, India, Indonesia, Malaysia, Singapore, Australia, New Zealand, Turkey, South Africa, and GCC Countries |
| Key Market Segments Covered | Test Type, End User, Region |
| Key Companies Profiled | Thermo Fisher Scientific Inc.; Roche Molecular Systems Inc.; bioMérieux SA; InBios International Inc.; NovaTec Immundiagnostica GmbH; Euroimmun AG (Sub. PerkinElmer); Quest Diagnostics; Certest Biotec S.L.; Response Biomedical Corp.; Chembio Diagnostic Systems Inc.; Abbott Laboratories |
| Pricing | Available upon Request |
The global arthropod-borne viral infections testing market holds a valuation of US$ 1.3 Bn in 2022.
ELISA-based tests account for 52% of the global arthropod-borne viral infections testing market share.
Demand for arthropod-borne viral infections testing is predicted to evolve at a CAGR of 5.6% from 2022 to 2029.
Sales of arthropod-borne viral infections testing kits are projected to reach US$ 1.9 Bn by 2029.
Leading arthropod-borne viral infections testing companies are Roche Molecular Systems Inc., bioMérieux SA, InBios International Inc., NovaTec Immundiagnostica GmbH, Euroimmun AG (Sub. PerkinElmer), Quest Diagnostics, Certest Biotec S.L., Response Biomedical Corp., Chembio Diagnostic Systems Inc., and Abbott Laboratories.
| Estimated Size, 2025 | USD 8,125.2 million |
|---|---|
| Projected Size, 2035 | USD 11,890.2 million |
| CAGR (2025 to 2035) | 3.9% |
| Estimated Size, 2024 | USD 964.4 million |
|---|---|
| Projected Size, 2034 | USD 1,601.1 million |
| Value-based CAGR (2024 to 2034) | 5.2% |
| Expected Base Year Value (2024) | USD 40,845.2 million |
|---|---|
| Anticipated Forecast Value (2034) | USD 55,379.1 million |
| CAGR (2024 to 2034) | 3.1% |
| Market Value (2023) | USD 8.86 billion |
|---|---|
| Market Value (2033) | USD 15.60 billion |
| Projected CAGR (2023 to 2033) | 5.8% |
Explore In-vitro Diagnostics Devices Insights
View Reports
Arthropod-borne Viral Infections Testing Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
